MICHAEL W. BONNEY - Corporate Board Profile

abrdn Healthcare Investors

Filing Date	Source Excerpt
2012-04-30	Michael W. Bonney: Mr. Bonney is the President, Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Governance and Nominating Committees of the Funds.
2013-04-25	Michael W. Bonney: Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation, Governance and Nominating Committees of the Fund. ... Compensation Table For the fiscal year ended September 30, 2012 ... Michael W. Bonney $17,000 + $17,000 = $34,000 total compensation.
2014-04-30	Michael W. Bonney: Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of the Fund. ... The members of the Committee are Mr. Bonney, Dr. Jain and Ms. Stebbins. Mr. Bonney is the Chairman of the Committee. ... The members of the Fund's Valuation Committee are Mr. Bonney, Dr. Omstead, Mr. Pohotsky and Mr. Reardon. Mr. Pohotsky is the Chairman of the Fund's Valuation Committee. ... For the fiscal year ended September 30, 2013, the Fund paid an annual fee of $18,000 to its Independent Trustees, $500 to its Audit and Valuation Committee members and $250 to its Nominating and Governance Committee members. Additionally, the Fund paid each Independent Trustee $1,000 for each Board and Committee meeting attended in person and $250 for each Board and Committee meeting attended by telephone. The Chairman of the Board, the Chairman of the Audit Committee and the Chairman of the Valuation Committee of the Fund each received an additional annual fee of $2,500. The Chairman of the Nominating Committee and the Chairman of the Governance Committee of the Fund each received an additional annual fee of $1,250. ... Compensation Table ... Michael W. Bonney ... Total Compensation ... $53,000.
2015-04-20	Michael W. Bonney (56)100 Federal Street, 19th Floor,Boston MA 02110 Trustee of HQH, HQL and THQ; Member of each Fund's Valuation and Governance and Nominating Committees. Compensation Table: Total Compensation from All Funds in Fund Complex Paid to Trustees $75,750.
2016-04-18	Michael W. Bonney: Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Celgene Corporation, Global Blood Therapeutics and Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.
2017-04-18	Michael W. Bonney: Mr. Bonney was a Partner at Third Rock Ventures until 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. ... Compensation Table ... Michael W. Bonney ... Total Compensation from All Funds in Fund Complex Paid to Trustees $92,479.
2018-04-18	Michael W. Bonney: Mr. Bonney is the Chief Executive Officer and Chairman of the Board of Trustees of Kaleido Biosciences and was a Partner at Third Rock Ventures until 2016 and Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Magenta Therapeutics, Sarepta Therapeutics, Celgene Corporation, Global Blood Therapeutics, Whitehead Institute, Alnylam Pharmaceuticals, Inc. and Gulf of Maine Research Institute and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.

abrdn Life Sciences Investors

Filing Date	Source Excerpt
2012-04-30	Michael W. Bonney: Mr. Bonney is the President, Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Governance and Nominating Committees of the Funds.
2013-04-25	Michael W. Bonney: Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation, Governance and Nominating Committees of the Fund. ... Compensation Table ... Michael W. Bonney ... Total Compensation from both Funds in Fund Complex Paid to Trustees $34,000.
2014-04-30	Michael W. Bonney (55)2 Liberty Square, 9th Floor,Boston MA 02109 Trustee of HQH and HQL; Member of each Fund's Valuation and Governance and Nominating Committees. ... He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of the Fund. ... The members of the Fund's Valuation Committee are Mr. Bonney ... The members of the Committee are Mr. Bonney ... Mr. Bonney is the Chairman of the Committee. ... For the fiscal year ended September 30, 2013 ... Michael W. Bonney ... Total Compensation from both Funds in Fund Complex Paid to Trustees $53,000.
2015-04-20	Michael W. Bonney (56)100 Federal Street, 19th Floor,Boston MA 02110 Trustee of HQH, HQL and THQ; Member of each Fund's Valuation and Governance and Nominating Committees. Compensation: $75,750
2016-04-18	Michael W. Bonney: Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Celgene Corporation, Global Blood Therapeutics and Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College. Michael W. Bonney (57) 100 Federal Street, 19th Floor, Boston MA 02110: Trustee of HQH, HQL, THQ and THW; Member of each Fund's Valuation and Governance and Nominating Committees. Compensation: $97,605.
2017-04-18	Michael W. Bonney: Mr. Bonney was a Partner at Third Rock Ventures until 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of the Fund. Mr. Bonney is also a Director of Magenta Therapeutics, Celgene Corporation, Global Blood Therapeutics, Revolutions Medicine, Whitehead Institute, Alnylam Pharmaceuticals, Inc. and Gulf of Maine Research Institute and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.
2018-04-18	Michael W. Bonney: Mr. Bonney is the Chief Executive Officer and Chairman of the Board of Trustees of Kaleido Biosciences and was a Partner at Third Rock Ventures until 2016 and Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of the Fund. Mr. Bonney is also a Director of Magenta Therapeutics, Sarepta Therapeutics, Celgene Corporation, Global Blood Therapeutics, Whitehead Institute, Alnylam Pharmaceuticals, Inc. and Gulf of Maine Research Institute and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College. Compensation Table: Michael W. Bonney $22,375; Total Compensation $88,750.

ALNYLAM PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2015-03-10	Mr. Bonney served as the Chief Executive Officer of Cubist Pharmaceuticals Inc., a biopharmaceutical company, from June 2003 until his retirement in December 2014.
2016-03-17	Mr. Bonney has been a Partner at Third Rock Ventures, a venture capital firm, since January 2016. Mr. Bonney previously served as the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Merck & Co., Inc.), from June 2003 until his retirement in December 2014.
2017-03-17	Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company.
2019-03-21	Mr. Bonney possesses over 30 years of operational, commercial and senior management experience in the biopharmaceutical industry, including his long tenure as the Chief Executive Officer and a director of Cubist.
2020-03-23	Mr. Bonney possesses over 30 years of operational, commercial and senior management experience in the biopharmaceutical industry, including his long tenure as the Chief Executive Officer and a director of Cubist.
2021-04-02	Mr. Bonney has served as the Chair of the board of directors of Kaleido Biosciences, Inc., a biotechnology company, since June 2017.
2022-04-05	Mr. Bonney possesses over 30 years of operational, commercial and senior management experience in the biopharmaceutical industry.
2023-04-03	Mr. Bonney possesses over 30 years of operational, commercial and senior management experience in the biopharmaceutical industry, including his long tenure as the Chief Executive Officer and a director of Cubist.
2025-03-24	Mr. Bonney possesses over 30 years of operational, commercial and senior management experience in the biopharmaceutical industry, including his long tenure as the Chief Executive Officer and a director of Cubist.

BRISTOL MYERS SQUIBB CO

Filing Date	Source Excerpt
2020-03-25	Michael W. Bonney Director Since: 2019 Age: 61 Board Committees • Audit Committee • Science & Technology Committee ...Michael W. Bonney received $48,413 total compensation in 2019.
2021-03-25	Michael W. Bonney Director Since: 2019Age: 62 Board Committees • Audit Committee • Science & Technology Committee Other Public Boards • Kaleido Biosciences, Inc. (Chair) • Alnylam Pharmaceuticals (Chair) • Magenta Therapeutics (Chair) Former • Celgene Corporation • Global Blood Therapeutics, Inc. • Sarepta Therapeutics Inc. • Syros Pharmaceuticals Experience • Chair of the Board of Kaleido Biosciences, Inc.(2020-present); Executive Chair of the Board of Kaleido Biosciences, Inc. (2018-2020); Chief Executive Officer and Chairman (2017-2018) • Partner of Third Rock Ventures, LLC (January-July 2016) • Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. until acquired by Merck & Co., Inc. (2003-2014) • Vice President, Sales and Marketing at Biogen, Inc. (1998-2001) • Spent eleven years at Zeneca Pharmaceuticals (1984-1995) • Chair of the Board of Trustees of Bates College (2010–2019) Key Skills and Experience • Public Company CEO / CFO • Healthcare • Financial • Science / Technology / Innovation Other • Director of Gulf of Maine Research Institute • Board of Trustees of the non-profit Rare

Filing Date

Source Excerpt

2020-03-25

Michael W. Bonney Director Since: 2019 Age: 61 Board Committees • Audit Committee • Science & Technology Committee ...Michael W. Bonney received $48,413 total compensation in 2019.

2021-03-25

Michael W. Bonney Director Since: 2019Age: 62 Board Committees • Audit Committee • Science & Technology Committee Other Public Boards • Kaleido Biosciences, Inc. (Chair) • Alnylam Pharmaceuticals (Chair) • Magenta Therapeutics (Chair) Former • Celgene Corporation • Global Blood Therapeutics, Inc. • Sarepta Therapeutics Inc. • Syros Pharmaceuticals Experience • Chair of the Board of Kaleido Biosciences, Inc.(2020-present); Executive Chair of the Board of Kaleido Biosciences, Inc. (2018-2020); Chief Executive Officer and Chairman (2017-2018) • Partner of Third Rock Ventures, LLC (January-July 2016) • Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. until acquired by Merck & Co., Inc. (2003-2014) • Vice President, Sales and Marketing at Biogen, Inc. (1998-2001) • Spent eleven years at Zeneca Pharmaceuticals (1984-1995) • Chair of the Board of Trustees of Bates College (2010–2019) Key Skills and Experience • Public Company CEO / CFO • Healthcare • Financial • Science / Technology / Innovation Other • Director of Gulf of Maine Research Institute • Board of Trustees of the non-profit Rare

Sarepta Therapeutics, Inc.

Filing Date	Source Excerpt
2018-04-26	Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. ... The current members of the audit committee are M. Kathleen Behrens, Ph.D. (Chairwoman), Richard J. Barry and Michael W. Bonney. ... The cash compensation paid to our non-employee directors for their services on our Board and its committees during 2017 was as described above. ... Michael W. Bonney $0 cash, $415,630 option awards, total $415,630.
2019-04-26	Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. ... The current members of the audit committee are M. Kathleen Behrens, Ph.D. (Chairwoman), Richard J. Barry and Michael W. Bonney. ... The following table sets forth compensation information for our current and former non-employee directors that served on our Board in 2018. ... Michael W. Bonney $34,916 cash, $244,216 stock awards, $166,114 option awards, total $445,246.

Filing Date

Source Excerpt

2018-04-26

Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. ... The current members of the audit committee are M. Kathleen Behrens, Ph.D. (Chairwoman), Richard J. Barry and Michael W. Bonney. ... The cash compensation paid to our non-employee directors for their services on our Board and its committees during 2017 was as described above. ... Michael W. Bonney $0 cash, $415,630 option awards, total $415,630.

2019-04-26

Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. ... The current members of the audit committee are M. Kathleen Behrens, Ph.D. (Chairwoman), Richard J. Barry and Michael W. Bonney. ... The following table sets forth compensation information for our current and former non-employee directors that served on our Board in 2018. ... Michael W. Bonney $34,916 cash, $244,216 stock awards, $166,114 option awards, total $445,246.